Innate Pharma (IPH) — Strategic Asset Allocation Index
Innate Pharma (IPH) has a Strategic Asset Allocation Index of 298.3% as of June 2025. Strategic assets (PP&E of €4.96 Million plus long-term investments of €10.39 Million) total €15.35 Million, measured against net assets of €5.14 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Innate Pharma Strategic Asset Allocation Index (2003–2024)
This chart shows how Innate Pharma's Strategic Asset Allocation Index has evolved across 22 annual periods from 2003 to 2024. As of June 2025, the index stands at 298.3%, representing strategic assets of €15.35 Million against net assets of €5.14 Million EUR. Explore IPH cash flow metrics to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Innate Pharma (2003–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Innate Pharma from 2003 to 2024, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Innate Pharma.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 174.5% | €15.41 Million | €5.13 Million | €10.28 Million | €8.83 Million | ▲ +143.4 pp |
| 2023 | 31.1% | €16.12 Million | €6.32 Million | €9.80 Million | €51.90 Million | ▼ -49.6 pp |
| 2022 | 80.6% | €43.66 Million | €8.54 Million | €35.12 Million | €54.15 Million | ▲ +34.0 pp |
| 2021 | 46.6% | €50.05 Million | €10.17 Million | €39.88 Million | €107.44 Million | ▲ +14.1 pp |
| 2020 | 32.5% | €50.63 Million | €11.69 Million | €38.93 Million | €155.97 Million | ▲ +10.1 pp |
| 2019 | 22.4% | €48.68 Million | €11.67 Million | €37.01 Million | €217.42 Million | ▼ -4.8 pp |
| 2018 | 27.1% | €45.40 Million | €10.22 Million | €35.18 Million | €167.24 Million | ▼ -55.7 pp |
| 2017 | 82.8% | €71.20 Million | €10.73 Million | €60.47 Million | €85.96 Million | ▲ +34.0 pp |
| 2016 | 48.8% | €42.07 Million | €9.09 Million | €32.98 Million | €86.17 Million | ▼ -6.1 pp |
| 2015 | 54.9% | €39.55 Million | €6.30 Million | €33.24 Million | €72.07 Million | ▲ +46.8 pp |
| 2014 | 8.1% | €6.01 Million | €5.93 Million | €84.00K | €74.63 Million | ▼ -8.1 pp |
| 2013 | 16.2% | €6.53 Million | €6.26 Million | €272.00K | €40.29 Million | ▼ -13.0 pp |
| 2012 | 29.2% | €6.82 Million | €6.82 Million | €- | €23.36 Million | ▲ +5.0 pp |
| 2011 | 24.2% | €6.44 Million | €6.44 Million | €- | €26.62 Million | ▲ +2.3 pp |
| 2010 | 21.9% | €7.33 Million | €7.33 Million | €- | €33.52 Million | ▲ +5.0 pp |
| 2009 | 16.9% | €7.94 Million | €7.94 Million | €- | €47.12 Million | ▼ -3.8 pp |
| 2008 | 20.6% | €8.52 Million | €8.52 Million | €- | €41.34 Million | ▲ +17.6 pp |
| 2007 | 3.1% | €1.52 Million | €1.52 Million | €- | €49.61 Million | ▲ +1.7 pp |
| 2006 | 1.4% | €774.00K | €774.00K | €- | €56.37 Million | ▼ -2.0 pp |
| 2005 | 3.4% | €684.00K | €684.00K | €- | €20.07 Million | ▼ -0.2 pp |
| 2004 | 3.6% | €895.00K | €895.00K | €- | €25.01 Million | ▼ -2.3 pp |
| 2003 | 5.9% | €887.00K | €887.00K | €- | €15.11 Million | — |